Clinical trial
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects…
NCT00123474 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00123474 |
|---|---|
| Title | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML |
| Official title | A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or… |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic, Chronic-Phase |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 724 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Jul 1, 2014 |
| First posted | Jul 25, 2005 |
| Last update posted | Aug 25, 2016 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Germany, Hungary and 19 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: